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With the advent of recombinant technology, a wide variety of biocompatible therapeutic proteins 
can be produced with relative ease. These proteins are formulated and subsequently administered in 
patients to treat various of diseases in a more effective and targeted manner. At the level of 
formulation development, protein molecules can be physically and/or chemically-conjugated to a 
wide array of naturally-occurring, semi-synthetic and synthetic biomaterials to form different types 
of protein delivery systems. Depending on their architecture and the extent of protein-scaffold 
interactions, these delivery systems can modify the pharmacokinetic and pharmacodynamic 
properties of the proteins. The versatility of polymer-based protein delivery systems such as 
micro/nanoparticles, hydrogels, porous scaffolds and fibrous scaffolds means it is possible to alter 
the spatial distribution of the protein load within the system as well as the protein release kinetics. 
These can then influence the ability of the protein molecules to exert their effects in their immediate 
microenvironments, be it to kill cancer cells or to recruit stem/progenitor cells. In this Chapter we 
discuss the production of protein therapeutics and the application of polymer-based biodegradable 
delivery systems for these proteins which include nanoparticles and scaffolds. We also include 










The previous two decades have seen a remarkable progress in biotechnology that enables 
production of many proteins for use in biomedical research. To improve their therapeutic values, 
much attention has been dedicated to prolonging the biological activity of these proteins after 
administration in patients. Due to the challenges faced by proteins in crossing biological barriers 
and target disease sites a variety of organic and inorganic biomaterials have been developed. It is 
ranging from basic drug first delivery system such as polymer system for delivery of 
biomacromolecules, described in 1976 to smarter systems with capabilities of stimulating 
therapeutic release and local biological action in response to interactions with the surrounding 
environment (1,2). Proof of concept has already been obtained in the field of regenerative medicine 
(3,4) and in cancer therapy (5,6). A common approach involves incorporating the protein molecules 
into an appropriate matrix that permits gradual release of the protein load. In doing so, the matrix 
limits the exposure of proteins from proteases and neutralizing antibodies that may be present in the 
immediate physiological environment, thus preventing them from undergoing rapid degradation. 
Polymers have been widely-used to produce protein-loaded matrices due to the high versatility of 
this material group. By changing the type of monomers, controlling the polymerization conditions 
or functionalizing the polymer chains with chemical groups of interest, the physicochemical and 
biological properties of the polymer matrix, including surface charge, hydrophobicity, 







2. Protein Therapeutics  
2.1 A brief history and rationale 
Proteins have the most dynamic and diverse role of any macromolecule in the body. They act as 
catalysts to biochemical reactions by forming receptors and channels in the membranes. 
Furthermore, proteins provide intracellular and extracellular scaffolding support and they transport 
molecules within the cells or from one organ to another (7). It has been estimated that there are 
approximately 25,000–40,000 different genes in the human genome and with alternative splicing of 
genes and post-translational modification of proteins the number of distinct functional proteins is 
likely to be much higher (8,9). The great number of functional proteins could pose vast challenges 
to modern medicine, as disease may result when any one of these proteins contains mutations or 
other abnormalities, or is present in abnormally high or low concentration. These proteins however 
may also present immense possibilities in terms of development of protein therapeutics to alleviate 
disease. It is for this reason that they have progressively become the forerunners in 
biopharmaceutics. Protein therapeutics can be grouped into molecular types that include: antibody-
based drugs, anticoagulants, blood factors, bone morphogenetic proteins (BMPs), enzymes, fusion 
proteins, growth factors, hormones, interferons, interleukins, and thrombolytics (10,11). Protein 
therapeutics have also been classified based on their pharmacologic activity as drugs that: i) replace 
a protein that is deficient or abnormal, ii) supplement an existing pathway, iii) provide a novel 
function or activity, iv) interfere with a molecule or organism, or iv) deliver a payload such as a 
radionuclide, cytotoxic drug, or protein effector (7).  
Proteins first emerged as a major class of pharmaceuticals in the 1980s, with a majority of them 
mainly developed for therapeutics and a small number for diagnostics and vaccines (10). More than 
three decades later, a better understanding of the molecular biology and biochemistry behind these 
macromolecules and their role in various body functions and pathological conditions has led to the 
realisation of enormous therapeutic applications for proteins (12). Advances in the development of 
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protein therapeutics has demonstrated that these molecules offer several advantages over the more 
conventional small molecule drugs (Fig. 11.1).  
The first reported use of protein therapeutics was in the 1920s when Insulin that was purified from 
bovine and porcine pancreas was used as a life-saving daily injection for patients suffering from 
type 1 diabetes mellitus (13). The low availability of animal pancreases for purification of insulin, 
the high cost of the purification and the immunological reaction of some patients to animal insulin 
hindered the widespread use of this protein (14). In 1982 Insulin became the first FDA approved 
human protein therapeutic derived from recombinant DNA technology 
(https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/recombinant-
dna-technology)  and has since become the major therapy for type 1 and type 2 diabetes mellitus 
(14,15). Soon after, other recombinant human proteins were developed as therapeutics to replace the 
natural proteins deficient in some patients (e.g., growth hormone) or boost existing pathways (e.g., 
interferon-α, tissue plasminogen activator, and erythropoietin) (7, 16). 
Recombinant production of proteins is highly favoured over purification of proteins from their 
native source. A small number of non-recombinant proteins purified from their native source have 
been reported, such as pancreatic enzymes from hog and pig pancreas (17) and alpha-1 proteinase 
inhibitor from pooled human plasma (18). This strategy however has proven to be rather 
challenging and expensive. In this regard, the production of therapeutic proteins by genetic 
engineering using recombinant DNA technology has presented great opportunities towards 
overcoming the challenges faced with conventional non-recombinant proteins. In addition to 
availability in sufficient quantities and the reduced risk of immunological rejection, recombinant 
technology allows the modification of proteins or the selection of particular gene variants to 
improve function or specificity and enables the production of proteins that provide novel functions 
or activity (7). Thus modern therapeutic proteins are largely produced by recombinant technology.  
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In the field of cancer treatment, it has been shown that a synergic effect with ionizing radiation 
could occur upon exposure to BMPs. HrBMP4, for instance, is expressed in the embryonic cortex, 
indicating its role in the formation of mesoderm and neurogenesis, e.g. morphological 
differentiation of neural stem cells (19,20). A recent clinical trial carried out on the brain tumor 
glioblastoma (GBM) is in course after resection or biopsy of the tumor, using Convection Enhanced 
Delivery (CED) allowing increasing amounts of HrBMP4 solutions combined with Gd-DTPA and 
determining the extent of intra-tumor and interstitial drug delivery (21). HrBMP4, can indeed 
inhibit the proliferation of brain tumor stem cells, induce their morphological changes to a more 
differentiated phenotype and reduce their invasiveness (22,23). The possibility to abolish the 
tumor’s self-renewal potential by depleting the tumor stem cell compartment with a differentiating, 
non-toxic compound such as BMP4 is attractive because it could be used to render the stem cells 
more vulnerable to conventional post-surgery therapies. The differentiated cancer stem cells then 
could be better eliminated by external beam radiation or internal radiotherapy after loco-regional 
implantation (24). This is well illustrated by Stupp et al. (25) differentiating strategy: GBM is a 
heterogeneous tumor that can be initiated and maintained by a minority of CD133+ cancer stem-like 
cells that have a high tumorigenic potential and a low proliferation rate. Exposure to BMPs can 
force these CD133+ tumor cells into a more differentiated phenotype characteristic of the CD133− 
tumor bulk, abolishing their self-renewal potential and increasing their sensitivity to radiotherapy. 
Hence, BMP originally influences multiple signalling pathways originally involved organogenesis 
and lineage-specific differentiation but also in cancer stem-like cell maintenance.  
In the last decades, tissue engineering and regenerative medicine have emerged as promising 
strategies for bone reconstitution, with the ambition to circumvent the complications associated 
with traditional techniques. Bone tissue engineering aims to induce new functional bone 
regeneration via the synergistic combination of biomaterial scaffolds, cells, and signal factor 
therapy. Engineered bone tissues are considered as a potential alternative to the conventional use of 
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bone grafts, due to their limitless supply and no disease transmission. Bone scaffolds can be defined 
as an artificial temporary 3D matrix with micro- and nanostructures exhibiting biomimetic 
properties that provide a specific environment and architecture for bone growth and development 
(26,27). Scaffolds can be combined with different types of cells able to promote bone formation in 
vivo either by differentiating towards the osteogenic lineage or by releasing specific soluble 
cytokines. A challenge within scaffolds association with drugs and/or growth factors (e.g. BMPs) is 
that they can deliver those cytokines in the environment and exerting their therapeutic/regenerative 
effects (e.g. proliferation, differentiation). Interestingly, clinicians have demonstrated that such 
polymer-based systems can be injected or implanted locally thereby adverse effects. These two 
examples show that recombinant proteins of the same class  may exert therapeutic effects against 
different diseases depending on their ways of administration and their interactions with the 
biological microenvironment. 
 2.2 Limitations and challenges 
Tremendous effort has been invested in cellular engineering to optimise various hosts for protein 
production and there are many examples in which proteins have been used in therapy successfully. 
However, this kind of therapy has also presented various challenges. 
The use of protein therapeutics is often limited by their instability, solubility, distribution, method 
of administration and side effects (28,29). The stability of protein therapeutics is a critical issue. 
These molecules can suffer loss of activity in response to environmental triggers such as moisture 
or temperature, which can occur during storage or even when administered in vivo (30). 
Nevertheless, several reports have shown that optimized processing protocols allow that proteins 
encapsulated into polymer matrices or grafted to polymer scaffolds may preserve their native 
conformation and thus their bioactivity for several months (31-32). The permeability of protein 
therapeutics through barriers such as the skin, mucosal membranes and cellular membranes is 
substantially reduced due to high molecular mass, which leads to injection being the primary mode 
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of administration (33).  As many protein molecules have their therapeutic targets inside cells, 
challenges arise in transporting these molecules into the target cells without them breaking down 
while in the blood stream (28). The half-life of the therapeutic proteins can also be considerably 
reduced by proteases, protein-modifying chemicals or other clearance mechanisms in the body (34-
36). Stromal cell-Derived Factor 1 (SDF-1α), for example, can be cleaved by matrix 
metalloproteinase-2 and 9 (MMP-2/9) released during a traumatic event such as tumor resection in 
the case of GBM, resulting in loss of its chemotactic activity (37). 
BMP-2 has been previously isolated directly from bone. However, the limited yield and potential 
health risks associated with its isolation from allogeneic donor bone limited its clinical application 
(38). The expression of the recombinant BMP-2 in mammalian cell culture such as Chinese 
Hamster Ovarian (CHO) cells also generates low yields of protein and the procedure is relatively 
expensive (39,40). Eukaryotic systems such as yeast and animal cells were initially considered to 
produce recombinant BMP-2 to ensure adequate post translational modifications. Indeed, BMP-2 is 
a naturally glycosylated protein, but it has been discovered that glycosylation is not required for its 
function (41).  Recently several authors have reported the production of biologically active BMP-2 
expressed in E. coli. Although, the expressed BMP-2 was insoluble and formed inclusion bodies, 
active BMP-2 could be successfully refolded in vitro using specific refolding solutions and 
protocols (42-44).  BMP-2 is biologically active only in a dimeric form, which is stabilised by an 
inter-molecular disulphide bridge that connects two cysteines: Cys 114 and Cys 228 from two 
different BMP-2 protein molecules (45). The disulphide bridge that stabilises BMP-2 dimer ensures 
the interaction of the BMP-2 dimer with transmembrane serine/threonine kinase receptors on 
osteogenic cells; which activates proliferation and differentiation of osteoblast cells (42).  
Another challenge with protein therapy is the immune response that the body may build against the 
proteins. Virtually all therapeutic proteins generate some level of antibody response (46). There are 
cases where the immune response can neutralise the protein and can even cause a harmful reaction 
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in the patient. An example of such an immune response is the activation of B cells, which produce 
antibodies that bind to the proteins and reduce and possibly eliminate their therapeutic effects. Such 
antibodies can cause complications that can be life threatening. Thus the immune response of 
therapeutic proteins is a concern for researchers, manufacturers and clinicians (47). The uses of 
protein therapeutics in clinical animal trials usually do not effectively predict the response in 
humans. It is thus critical to evaluate the safety and efficacy of protein therapeutics and their 
probability to trigger antibody formation during development. 
Another shortcoming associated with protein therapeutics is the high production costs. Protein 
therapeutics are expensive and this may limit clinical applications as well as patient access. This 
high cost issue is further aggravated for protein therapeutics where multi-gram doses are needed for 
a treatment course, as is the case for some antibodies (48).  
Nano and micro-sized engineered materials have received considerable attention in modern 
pharmaceutics due to their potential to address the challenges encountered with conventional 
therapeutics. These materials can address issues associated with current pharmaceuticals such as 
extending product life, or can add to their performance and acceptability, either by increasing 
efficacy or improving safety and patient compliance (49,50). Targeted delivery and specific release 
can be achieved with these delivery systems via electrostatic interaction and pH or temperature 
dependent responses to controlled stimuli in vivo (51, 52).  
Current research is focused especially on developing biodegradable polymer materials that have 
shown significant therapeutic potential. Biodegradable polymers are natural or synthetic polymers 
that are able to degrade in vivo into biocompatible and toxicologically safe by-products that are 
subsequently resorbed or excreted by the body. Naturally occurring biodegradable polymers are 
widely explored because of their abundance in nature, biocompatibility and lower toxicity. Chitosan 
(53), hyaluronic acid (54), silk fibroin (55), cellulose (56) or collagen (57, 58) have been among the 
most investigated natural biodegradable polymers for protein delivery applications. However, their 
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use is challenging because of significant molecular weight distributions and batch-to-batch 
variability and the necessity to collaborate with companies that are able to purchase materials 
following clinical Good Manufacturing Practices (cGMP). On the other hand, cGMP synthetic 
biodegradable or bioeliminable polymers are commercially available with different and well-
defined compositions, molecular weights and degradation times. Aliphatic polyesters such as 
poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) have been among the most 
successfully used synthetic biodegradable polymers so far (59) . 
 3. Common forms of polymer-based protein delivery systems 
Common examples of polymer-based systems that have been utilized in recent years to deliver 
various drug molecules, including therapeutic proteins, include micro/nanoparticles, hydrogels and 
porous scaffolds (Fig. 11.2).  
 3.1 Micro/nanoparticles 
Micro/nanoparticles are injectable drug carriers that are usually prepared from hydrophobic 
polymers using straightforward processes such as solvent evaporation, phase separation and spray-
drying (60). In the solvent evaporation method, an organic phase is first formed by dissolving a 
hydrophobic polymer and the drug molecules to be encapsulated in a water-immiscible, volatile 
organic solvent. This phase is then dispersed in an aqueous phase containing stabilizers such as 
polyvinyl alcohol under continuous mechanical agitation to form an oil-in-water (O/W) emulsion. 
Drug-loaded particles are formed upon evaporation of the organic solvent from the inner phase at 
reduced or atmospheric pressure. The particles can then be collected by filtration or centrifugation, 
washed to remove the stabilizing molecules adsorbed to the particle surface and lyophilized to 
minimize hydrolytic degradation of the particles during long-term storage. However, the single 
emulsion technique may not be suitable for encapsulating hydrophilic drugs such as proteins as they 
tend to diffuse into the external aqueous phase during the emulsification step. Therefore, protein 
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molecules are first solubilized in an aqueous solvent, and then dispersed in a polymer-containing 
organic phase to form a primary water-in-oil (W/O) emulsion, followed by dispersion in another 
aqueous solvent to form the secondary O/W emulsion (61). The preparation of the primary W/O 
emulsion is also relevant to the phase separation method (Fig.11.3). Following this step, instead of 
adding an aqueous solvent, an organic solvent that is non-solvent to the dissolved polymer is 
gradually introduced to extract the solvent of the polymer and decrease its solubility. The phase 
separation of the polymer from its solution contributes to the formation of polymer-rich liquid phase 
(coacervate) that surrounds the inner drug-containing aqueous phase. Upon completion of the phase 
separation process, the coacervate solidifies to produce drug-loaded particles (62). An obvious 
drawback of this method is the requirement for a large volume of organic solvent. Recent work 
proposed the use of water-miscible organic solvents to dissolve the polymer. This replaces the need 
for organic solvents to induce phase separation as aqueous media can be used to extract the polymer 
solvent (63). Finally, in the spray-drying method, the W/O emulsion is sprayed into a heated 
chamber that leads to a spontaneous production of drug-loaded particles. This method is more rapid 
and convenient and has fewer processing parameters than the other two but is limited by the 
adhesion of the formed particles to the inner surfaces of the drying chamber (60). 
Due to their small size, micro/nanoparticles can be administered either directly to the intended site 
of action or into the systemic circulation to reach a desired location by passive or active targeting 
mechanisms (64) Several peptide-loaded polymer-based microparticle formulations have been 
approved by the FDA for clinical use. The first is Lupron Depot®, which received approval in 1989 
to provide sustained release of leuprolide acetate for prostate cancer treatment (65). A more recent 
example is Bydureon® that was approved in 2012, which releases exenatide to improve glycemic 
control in type 2 diabetes patients (66).  
In general, drug release from the particles is dependent upon the diffusion rate of the drug 
molecules and the degradation rate of the polymer-based matrix (60,65). However, as significant 
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proportion of the drug load can be weakly-adsorbed onto the large surface area of the 
micro/nanoparticles rather than incorporated in the polymer-based matrix, the drug release profile 
of this system is usually characterized by a huge initial burst that is followed by relatively short 
duration of release of the remaining drug load (67). Another disadvantage of this system is that the 
particles can move away from the targeted drug release site. The gradual translocation of the 
particles can become more prominent as the size of the particle decreases (64).  
 3.2 Hydrogels 
Hydrogels are three-dimensional networks of cross-linked hydrophilic polymers. The cross-linking 
can be mediated by the physical interactions (e.g. hydrogen bonds, electrostatic interactions) 
between the polymer chains (68,69) or the covalent bonds resulting from the use of chemical 
crosslinkers (e.g. carbodiimide, glutaraldehyde) (70-73). Most hydrogels are characterized by 
highly-porous structure. The pore size can range from 10 to 500 µm and is dependent upon the 
degree of cross-linking in the hydrogel matrix (74,75). The porous structure is responsible for the 
deformability of hydrogels, enabling them to conform to the shape of the site to which they are 
applied (76). Due to their hydrophilicity, water-soluble drug molecules can be conveniently loaded 
into the porous structure of a pre-formed hydrogel. However, this is not always true for high 
molecular weight drug molecules such as proteins, which have diffusive limitations to their 
partitioning into the pores of the hydrogel (77). The high dependency of the drug loading process on 
the pore size of the hydrogel also means that the loaded drug molecules are usually released rapidly 
at the site of application as the release process is governed mainly by the diffusion rate of the drug 
molecules through the pores (65). In fact, the release of hydrophilic molecules from a hydrogel 
system typically lasts for only several hours or days, shorter than the release durations achieved 
with micro/nanoparticles made of hydrophobic polymers (65). To counter this, several strategies to 
enhance drug-hydrogel interactions have been proposed, including the introduction of charged 
moieties into the hydrogel to boost ionic interactions (78)] and the direct conjugation of the drug 
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molecules to the hydrogel via covalent bond formation (79). Another credible strategy to prolong 
drug release is to load the drug molecules directly into the hydrogel matrix during the hydrogel 
fabrication process instead of loading into the pores of a pre-formed hydrogel (80). Finally, several 
groups proposed the strategy of pre-encapsulating drug molecules into suitable micro/nanoparticles 
and co-formulating the particulate system into the hydrogel matrix to achieve sustained drug release 
(81,82). 
As virtually any water-soluble polymer can be manipulated to produce this system, it is possible to 
obtain hydrogels with physicochemical and biological properties that are useful for a wide range of 
applications. Despite this, the number of hydrogel-based drug delivery systems approved for 
clinical use is still limited. An example of these is Regranex®, which consists of a 
carboxymethylcellulose gel that releases recombinant human platelet-derived growth factor 
(becaplermin) for the treatment of diabetic foot ulcers (76). 
In addition to the rapid drug release issue mentioned above, hydrogels possess several drawbacks 
that could limit its use for applications. Their poor mechanical strengths make them susceptible to 
premature dissolution (77), limiting the time window for acting in the micro-environment. In 
addition, in the absence of cell adhesive proteins, hydrogels tend to have low capacity for cell 
adhesion and attachment due to their low stiffness (83-85). 
3.3 Porous scaffolds 
Porous scaffolds refer to three-dimensional solid polymer matrices characterized by interconnected 
pores. Generally, they are formed by removing the solvent from a polymer solution that leads to the 
precipitation of the polymer molecules. Methods that have been employed to produce porous 
scaffolds include freeze-drying (86), particulate leaching (87) and gas foaming (88). In the first 
method, a polymer solution is initially frozen at a sub-zero temperature inside an airtight chamber. 
The pressure is then gradually decreased to vaporize the frozen liquid. As more and more solvent 
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evaporates, the polymer molecules precipitate and solidify to form a porous scaffold (86). In the 
particulate leaching method, a polymer solution is first mixed with salt particles of well-defined 
size. The solvent is subsequently removed under vacuum, leaving behind a solid polymer matrix 
loaded with salt particles. The subsequent leaching of the salt particles in distilled water results in 
the formation of a porous scaffold (87). Gas foaming is another common method used to make 
porous scaffolds. It relies on the nucleation and growth of gas bubbles in a polymer phase. 
Traditionally, the gas bubbles can be formed in situ by adding into the polymer phase a foaming 
agent such as ammonium bicarbonate, which generates inert gas such as CO2 when the pH of the 
system is decreased. A porous scaffold is formed upon removal of the dispersed gas bubbles from 
the polymer phase (88). Recently, supercritical fluids have been used as an alternative foaming 
agent. A supercritical fluid is any substance existing at a temperature and pressure above its critical 
point with an intermediate behavior between that of a liquid and a gas. The use of supercritical 
fluids is useful especially in making porous scaffolds from hydrophobic polymers as it circumvents 
the need for organic solvents during the preparation of the polymer phase. CO2 is widely-used as a 
supercritical fluid due to its minimal toxicity and low cost. Initially, polymers can be dissolved or 
plasticized in supercritical CO2. Upon depressurization of the system, the rapid expansion of the 
polymer phase as a result of the escape of CO2 gas leads to the formation of a porous scaffold (88-
90)].  
Similar to hydrogels, the use of porous scaffolds as a drug delivery system can be achieved by 
loading drug molecules into the pores of a pre-formed scaffold or incorporating them directly into 
the polymer phase before the scaffold fabrication process. A notable example of clinically-used 
porous scaffold-based drug delivery systems is Infuse®, which consists of a porous collagen 
scaffold that can be conveniently loaded with recombinant human bone morphogenetic protein-2 
(BMP-2) prior to administration in patients undergoing bone reconstruction procedure (91). 
Interestingly, the osteoinductive effect of this treatment relies on the chemotactic effect of BMP-2 
 15 
that induces the infiltration of mesenchymal stem cells (MSCs) into the pores of the collagen 
scaffold (92). The considerable mechanical strength of the scaffold means that it can withstand the 
traction forces generated during cell attachment and migration, thus sustaining the cell infiltration 
process. After initial proliferation, the MSCs are further stimulated by BMP-2 to undergo 
differentiation into bone-forming osteoblasts to enable new bone formation (93). Considering its 
huge clinical success, Infuse® presents a working example to the idea of using a chemotactic agent 
and a suitable scaffold to recruit a certain cell population. During a bone reconstruction surgery, the 
site of bone defect can be accessed and filled with the Infuse® bone graft consisting of BMP-2-
loaded porous collagen scaffolds to recruit mesenchymal stem cells (MSC) by chemotaxis. Upon 
infiltration into the injury site, the MSCs proliferate to increase their number before undergoing 
differentiation into the bone-forming osteoblasts, which secrete collagen and calcium-binding 
proteins to support the formation of mineralized bone tissues. 
3.4: Fibrous scaffolds as a polymer-based protein delivery system 
Fibrous scaffolds refer to scaffolds made of fibers with diameters on the order of several 
micrometers down to the tens of nanometers that are stacked layer-by-layer to form a three-
dimensional non-woven mesh (Fig. 11.4). Compared to micro/nanoparticles, hydrogels and porous 
scaffolds, the use of fibrous scaffolds as a delivery vehicle for therapeutic proteins is less common 
despite the multiple advantages offered by this system. This being said, the amount of research 
conducted to investigate the value of fibrous scaffolds in this field of application has increased 
steadily over the last two decades and multiple strategies for loading protein molecules into fibrous 
scaffolds have been proposed. 
Depending on the scaffold preparation technique, protein molecules can be embedded randomly in 
the fibers or partitioned into a specific fiber compartment as in the case of core-shell fibers 
(Fig.11.4). Chew et al. incorporated β-nerve growth factor (NGF) into fibers made of poly(ε-
caprolactone-ethyl ethylene phosphate) (PCLEEP) and examined the release profile. They observed 
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that the fibrous scaffold was able to sustain NGF release over a period of 90 days. They claimed 
that the slow degradation of PCLEEP contributed to the sustained release profile as NGF molecules 
could only be released by diffusion through the hydrophobic matrix of the fiber (94). On the other 
hand, Zhang et al. produced fibers with a core-shell structure as a vehicle to deliver bovine serum 
albumin (BSA). The outer shell was made of the hydrophobic PCL while the core compartment 
dispersed with the BSA molecules was made of the hydrophilic bioeliminable poly(ethylene glycol) 
(PEG). They reported that the core-shell system produced lower initial burst and longer duration of 
BSA release than fibers made of a single blend of PCL, PEG and BSA (95). Jiang et al. further 
explored the possibility of tuning the kinetics of protein release from core-shell fibers. They showed 
that by varying the mass ratio of PCL and PEG in the outer shell, the time to achieve complete 
release of BSA from the inner dextran core could be varied from one week to approximately one 
month. BSA release was accelerated with increasing PEG mass in the outer shell as its water-
solubility resulted in formation of pores through which BSA molecules could escape from the 
dextran core (96).  
Protein molecules may also be encapsulated into micro/nanoparticles prior to incorporation into 
fibrous scaffolds. Liu et al. prepared dextran-based nanoparticles loaded with basic fibroblast 
growth factor (FGF) that were subsequently embedded in poly(L-lactic acid) (PLLA) nanofibers. 
The duration of FGF release provided by the nanoparticle-nanofiber composite scaffold was 10 
days longer compared to what was achieved with nanofibers with directly embedded FGF (28 vs. 
18 days). In addition, the encapsulation of FGF into the dextran-based nanoparticles was also 
useful in reducing FGF structural changes during the fiber-making process (97). Qi et al. also 
adopted a similar approach. They incorporated BSA-loaded alginate microparticles into PLLA 
fibers and observed that the composite scaffold produced a longer duration of BSA release 
compared to the naked alginate microparticles (98). 
 17 
 3.5 Fibrous scaffolds with surface-bound protein molecules 
Alternatively, protein molecules can be loaded onto the surface of a pre-fabricated fibrous scaffold. 
This is especially useful when preparing protein-loaded fibrous scaffold using a hydrophobic 
polymer and there is a need to reduce the exposure of the protein molecules to organic solvents that 
are needed to solubilize the polymer prior to the scaffold fabrication step. The nano/micro 
dimension of the fibers confer a large surface area for adsorption of protein molecules (Fig.11.5). In 
fact, the amount of protein that can be adsorbed by a fibrous scaffold is generally four times greater 
than that afforded by a porous scaffold of equal volume (99). 
Immobilization of protein molecules to the surface of the fibers can be mediated by non-covalent 
interactions including hydrophobic interaction, van der Waals interaction, hydrogen bonding and 
electrostatic interaction. Heparin, a naturally-occurring polysaccharide, is known to have strong 
binding affinity for various growth factors (e.g. VEGF, transforming growth factor-β (TGF-β), 
fibroblast growth factor (FGF)), morphogens (e.g. BMP-2, BMP-7, BMP-14) (100) and ECM 
proteins (e.g. laminin) (101) due to its ability to form non-covalent interactions with these proteins. 
Therefore, heparin-functionalized fibrous scaffolds can be conveniently loaded with these proteins 
for local delivery applications. Casper et al. prepared PEG and poly(lactic-co-glycolic acid) 
(PLGA) nanofibers functionalized with low molecular weight heparin (LMWH) that were adsorbed 
with FGF. To slow down the dissociation of LMWH from the fibrous scaffold and thus prolong 
the duration of FGF release, LMWH was conjugated to PEG prior to its incorporation into the 
nanofibers. Although the FGF release profile was not assessed in their study, they reported that 
LMWH was retained in the fibrous scaffolds for at least 14 days (102). Furthermore, Patel et al. 
prepared heparin-functionalized PLLA nanofibers as a delivery vehicle for FGF and laminin. The 
adsorption of FGF and laminin to the surface of PLLA nanofibers was very stable, with less than 
0.1% of the total amount of immobilized protein molecules released into the surrounding solution 
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after 20 days. The slow release of the adsorbed protein molecules could be useful in certain 
neuroregenerative applications as the immobilized FGF was found to be as effective as its soluble 
counterpart in inducing neurite outgrowths from dorsal root ganglion tissues (103). Fiber surfaces 
can also be adsorbed with protein-loaded nanoparticles. Wei et al. prepared BMP-7-loaded PLGA 
nanoparticles that were subsequently immobilized onto PLLA nanofibers. They reported that the 
release kinetics of BMP-7 could be controlled by varying the degradation rate of the PLGA 
nanoparticles. However, as the nanoparticle surfaces were exposed to the surrounding solutions, a 
characteristic burst release could be observed with each formulation of BMP-7-loaded PLGA 
nanoparticles prepared in their study (104). 
Another widely-used method for functionalizing fiber surfaces with proteins is by chemical 
immobilization. This approach results in formation of covalent bonds between the fiber surfaces and 
the protein molecules. As the covalently-attached protein molecules cannot be easily desorbed from 
the fibers, this functionalization method is especially useful in many regenerative applications, 
where long-term immobilization of protein molecules in the fibrous scaffold is often necessary for 
the reparative actions to take place. Primary amine and carboxyl groups are the most common 
example of functional groups utilized in covalent conjugation of fibers and protein molecules. Many 
groups have prepared polymer-based nanofibers functionalized with carboxyl groups that can be 
activated by a combination of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) for subsequent conjugation with primary amine groups present in 
protein molecules. Ye et al. prepared nanofibers from poly(acrylonitrile-co-maleic acid) 
(PANCMA) that were subsequently functionalized with lipase. However, the immobilized lipase 
molecules were found to have lower enzymatic activities than their soluble counterparts (105). A 
similar loss in activity was also reported by a group that functionalized polystyrene (PS) nanofibers 
with α-chymotrypsin (106). There are two possible explanations for the partial inactivation of the 
immobilized enzymes. First, the immobilization process may introduce covalent alterations to the 
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active sites of the enzyme. The other is that direct conjugation of protein molecules to the fiber 
surfaces may cause certain parts of the immobilized molecules to be sterically inaccessible to their 
corresponding ligands (107). To address the latter issue, several polymer-based linkers have been 
utilized to introduce a physical gap between the immobilized molecules and the fiber surfaces. To 
obtain these linkers, primary amine-terminated hydrophilic polymers such as PEG-diamine can be 
chemically-conjugated to a hydrophobic polymer such as PCL and PLGA. The linker can then be 
mixed with an unconjugated hydrophobic polymer to prepare fibers displaying primary amine 
groups on their surface that can be conjugated with protein molecules. Choi et al. immobilized EGF 
on the surface of fibers composed of PCL and PCL-PEG-NH2 for wound healing applications. They 
showed that the EGF-functionalized fibers were able to induce differentiation of keratinocytes to a 
greater extent than fibers supplemented with EGF solution. The enhanced activity of the former 
could potentially be attributed to the fact that covalently-immobilized EGF could be better retained 
at the wound site and thus was able to induce more durable pro-differentiation signals in the locally-
residing keratinocytes (108). Kim et al. also utilized a polymer-based linker to conjugate lysozyme 
to the surface of PLGA nanofibers. The immobilized lysozyme displayed comparable activity to its 
soluble counterpart (109). This is opposite to the significant loss of enzymatic activities observed 
with direct conjugation of enzyme molecules to the fiber surfaces as discussed above.  
4. Conclusions 
With the advent of recombinant technology, a wide variety of biocompatible therapeutic proteins 
can be manufactured with relative ease. These proteins would then be carefully formulated and 
subsequently administered in patients to address different types of diseases more effectively and 
selectively. At the level of formulation development, protein molecules can be physically and/or 
chemically-conjugated to a wide array of naturally-occuring, semi-synthetic and synthetic 
biomaterials to form different types of protein delivery systems. Depending on their architecture 
and the extent of protein-scaffold interactions, these delivery systems can modify the 
 20 
pharmacokinetic (PK) and pharmacodynamic (PD) properties of the protein molecules. The 
versatility of polymer-based protein delivery systems such as micro/nanoparticles, hydrogels, 
porous scaffolds and fibrous scaffolds means it is possible to alter the spatial distribution of the 
protein load within the system as well as the protein release kinetics. These can then influence the 
ability of the protein molecules to exert the intended effects in their immediate microenvironments, 
be it to kill cancer cells or to recruit stem/progenitor cells. From a pharmaceutical development 
perspective, the design of a protein delivery system should be commenced only after the attainment 
of an in-depth understanding of the PK/PD profile of the protein of interest for a given medical 
application. Therefore, a close communication between formulation scientists, molecular biologists, 
PK/PD scientists and clinicians are crucial to ensure successful development of protein delivery 
systems that are fit for pre-clinical proof-of-concept and subsequently clinical studies.  
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Figure 11.1: Advantages of protein therapeutics for clinical applications 
Figure 11.2: Common polymer-based systems for drug delivery applications. 
Figure 11.3: Examples of micro/nanoparticle preparation process. 
Figure 11.4: A simplified representation of a fibrous scaffold and its internal structure. 
Figure 11.5: Different modes of protein loading into a fibrous scaffold. Adapted from 
(106,107). 
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